A Study of Anlotinib in Patients With Hepatocellular Carcinoma

NCT02809534 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Anlotinib

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.